Asenapine vs Risperidone (Risperdal Consta)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Asenapine
Marketed by AbbVie and partners
NCT00212784 · Phase 3 · completed
This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.
Reported efficacy
Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint): Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint (unclear)
Result source: NCT00212771
Risperidone (Risperdal Consta)
Marketed by Johnson & Johnson
NCT00253136 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 458 participants, using change in a standard psychiatric symptom scale as the primary measure. The FDA product label for this pivotal trial reports that 47% of patients on the 25 mg dose showed a clinically meaningful improvement, compared with 17% on placebo.
Reported efficacy
Change from baseline to the end of double-blind treatment in the PANSS (Positive and Negative Syndrome Scale for Schizophrenia) total score: Clinical improvement (>=20% PANSS total score reduction): 47% (Risperdal Consta 25mg) vs 17% (placebo); design (randomized, double-blind, placebo-controlled, 25/50/75mg arms, 12 weeks, Nov 1999-Dec 2000) and this was the pivotal FDA-registration trial for Risperdal Consta, matching NCT00253136's CT.gov record exactly. (met)
Result source: NCT00253136
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Asenapine | Risperidone (Risperdal Consta) |
|---|---|---|
| PANSS total, change | -25.5 vs -17.8−7.7 vs placeboNCT0119025418 other results
| -9.3 vs -1.1vs QuetiapineNCT002164761 other result
|
| CGI-S, change | -1.3 vs -0.8−0.5 vs placeboNCT0119025417 other results
| -0.3 vs 0.1vs QuetiapineNCT002164761 other result
|
| PANSS response | 39.3% vs 20.7%+18.6 vs placeboNCT010981101 other result
| —Not posted · NCT00216580 |
| PSP, change | —Not posted · NCT00212771 | 5.3 vs 6.0vs Risperidone TabletsNCT00992407 |
| Relapse (% of patients) | —Not posted · NCT00212771 | 5% vs 32.6%vs RisperidoneNCT003305511 other result
|
PANSS total, change
- Asenapine
- -25.5 vs -17.8−7.7 vs placeboNCT01190254
18 other results
- -21.7 vs -16.2 NCT01617187
- -12.2 vs -0.9 NCT01098110
- -14.2 vs -0.9 NCT01098110
- -23.7 vs -17.8 NCT01190254
- -17.4 vs -16.2 NCT01617187
- -19 vs -15.4 NCT01617187
- -17.1 vs -15.5 NCT01617187
- -14.8 vs -13.2 NCT01617187
- -12.5 vs -10.7 NCT01617187
- -9.1 vs -7.1 NCT01617187
- -4.9 vs -4.8 NCT01617187
- -17 vs -15.4 NCT01617187
- -12.3 vs -15.5 NCT01617187
- -12 vs -13.2 NCT01617187
- -9.9 vs -10.7 NCT01617187
- -7.2 vs -7.1 NCT01617187
- -4 vs -4.8 NCT01617187
- -21 vs -27.5 NCT00212784
- Risperidone (Risperdal Consta)
- -9.3 vs -1.1vs QuetiapineNCT00216476
1 other result
- -11.7 vs -13 NCT00992407
CGI-S, change
- Asenapine
- -1.3 vs -0.8−0.5 vs placeboNCT01190254
17 other results
- -1.2 vs -1 NCT01617187
- -0.7 vs -0.2 NCT01098110
- -1.1 vs -0.8 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -0.8 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.2 vs -0.2 NCT01617187
- -0.8 vs -0.2 NCT01098110
- -1.1 vs -0.8 NCT01190254
- -0.9 vs -1 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -0.7 vs -0.8 NCT01617187
- -0.6 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.1 vs -0.2 NCT01617187
- Risperidone (Risperdal Consta)
- -0.3 vs 0.1vs QuetiapineNCT00216476
1 other result
- -0.6 vs -0.7 NCT00992407
PANSS response
- Asenapine
- 39.3% vs 20.7%+18.6 vs placeboNCT01098110
1 other result
- 43.8% vs 20.7% NCT01098110
- Risperidone (Risperdal Consta)
- —Not posted · NCT00216580
PSP, change
- Asenapine
- —Not posted · NCT00212771
- Risperidone (Risperdal Consta)
- 5.3 vs 6.0vs Risperidone TabletsNCT00992407
Relapse (% of patients)
- Asenapine
- —Not posted · NCT00212771
- Risperidone (Risperdal Consta)
- 5% vs 32.6%vs RisperidoneNCT00330551
1 other result
- 34.4% vs 16.1% NCT00246259
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Asenapine: 5 of 5 rows · Risperidone (Risperdal Consta): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Asenapine Rows use multiple source trials | Risperidone (Risperdal Consta) Rows use multiple source trials |
|---|---|---|
| PANSS Total absolute change · score No placebo or comparator arm | -11.08 score @ 52wka,b,c,d NCT01244828 · Phase 3 · registry result, not featured evidence show 1 more dose-5.48 score NCT01244828 · Phase 3 · registry result, not featured evidence | 18.24 score @ 96wkb,c,d NCT00269919 · Phase 4 · registry result, not featured evidence |
| Dropout rate | 44.4%5 mg twice dailye NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results16.7%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 54.8%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 1%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 49.7% NCT01244828 · Phase 3 · registry result, not featured evidence 35.2%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 40.1%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 50%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.9%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 17.3%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 33.7% NCT00174265 · Phase 3 · registry result, not featured evidence 50.4% NCT00145496 · Phase 3 · registry result, not featured evidence 30.4% NCT00150176 · Phase 3 · registry result, not featured evidence 15.7% NCT00265343 · Phase 3 · registry result, not featured evidence 67.7% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence 33.3%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 25%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 38.4%e NCT00132314 · Phase 3 show 14 more results5.9%CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 0%CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 14.3%HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 5.9%HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 25%Long-acting Injectable Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence —Long-acting Injectible Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence 29.5% NCT00539071 · Phase 4 · registry result, not featured evidence 83.8% NCT00992407 · Phase 4 · registry result, not featured evidence 26.5% NCT00130923 · Phase 4 · registry result, not featured evidence 31.8% NCT00216671 · Phase 4 · registry result, not featured evidence 63.6% NCT00246259 · Phase 4 · registry result, not featured evidence 67.5% NCT00269919 · Phase 4 · registry result, not featured evidence 45.3% NCT01726335 · Phase 4 · registry result, not featured evidence 31.9% NCT00216476 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 22.2%5 mg twice dailye NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 22.3%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 0%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 23.6% NCT01244828 · Phase 3 · registry result, not featured evidence 17%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 17.6%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 0%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 5.1%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 7.5%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 6.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 8.1% NCT00174265 · Phase 3 · registry result, not featured evidence 17.2% NCT00145496 · Phase 3 · registry result, not featured evidence 8.2% NCT00150176 · Phase 3 · registry result, not featured evidence 7.5% NCT00265343 · Phase 3 · registry result, not featured evidence 11.8% NCT00156065 · Phase 3 · registry result, not featured evidence —5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | —e NCT00132314 · Phase 3 show 14 more results—CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence —CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence —HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence —HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence —Long-acting Injectable Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence —Long-acting Injectible Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence — NCT00539071 · Phase 4 · registry result, not featured evidence 18.9% NCT00992407 · Phase 4 · registry result, not featured evidence — NCT00130923 · Phase 4 · registry result, not featured evidence 5.5% NCT00216671 · Phase 4 · registry result, not featured evidence 11.4% NCT00246259 · Phase 4 · registry result, not featured evidence — NCT00269919 · Phase 4 · registry result, not featured evidence 7.5% NCT01726335 · Phase 4 · registry result, not featured evidence 1.8% NCT00216476 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 0%5 mg twice dailye NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 20.4%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 4.4%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 5.2%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 8.9% NCT01244828 · Phase 3 · registry result, not featured evidence 5.7%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 2.8%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 12.5%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 3.6%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 2.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 3.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 4.7% NCT00174265 · Phase 3 · registry result, not featured evidence 12.3% NCT00145496 · Phase 3 · registry result, not featured evidence 3.1% NCT00150176 · Phase 3 · registry result, not featured evidence 6.7% NCT00265343 · Phase 3 · registry result, not featured evidence 14.1% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 51.3%e NCT00132314 · Phase 3 show 14 more results18.8%CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 8.3%CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 8.3%HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 0%HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence —Long-acting Injectable Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence 5%Long-acting Injectible Risperidone NCT00330551 · Phase 4 · registry result, not featured evidence 6.4% NCT00539071 · Phase 4 · registry result, not featured evidence 0% NCT00992407 · Phase 4 · registry result, not featured evidence 32.7% NCT00130923 · Phase 4 · registry result, not featured evidence 16.4% NCT00216671 · Phase 4 · registry result, not featured evidence 4.5% NCT00246259 · Phase 4 · registry result, not featured evidence 15.4% NCT00269919 · Phase 4 · registry result, not featured evidence 5.7% NCT01726335 · Phase 4 · registry result, not featured evidence 19.1% NCT00216476 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 5 mg twice dailye daytime drowsiness 22.2% NCT01549041 · Phase 4 · registry result, not featured evidence show 19 more results10 mg daily in the evening daytime drowsiness 0% NCT01549041 · Phase 4 · registry result, not featured evidence 5/10 mg BID nasopharyngitis 21.7% schizophrenia 10.8% somnolence 10.8% NCT01142596 · Phase 3 · registry result, not featured evidence 5 mg BID insomnia 15% (placebo 13.9%) headache 8.8% (placebo 2%) anxiety 7.1% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence 2.5 mg BID headache 10.3% (placebo 2%) insomnia 9.3% (placebo 13.9%) anxiety 7.2% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence nasopharyngitis 21% somnolence 12.7% weight increased 12.7% NCT01244828 · Phase 3 · registry result, not featured evidence 5 mg BID akathisia 11.4% (placebo 5.2%) hypoaesthesia oral 10.9% (placebo 3.4%) insomnia 9.7% (placebo 12.1%) NCT01098110 · Phase 3 · registry result, not featured evidence 10 mg BID schizophrenia 13.8% (placebo 24.1%) somnolence 12.2% (placebo 1.7%) akathisia 10.5% (placebo 5.2%) NCT01098110 · Phase 3 · registry result, not featured evidence accidental overdose 12.5% acne 12.5% akathisia 12.5% NCT01190267 · Phase 3 · registry result, not featured evidence somnolence 14.8% headache 6.6% sedation 5.1% NCT01190267 · Phase 3 · registry result, not featured evidence 5.0 mg BID somnolence 17% (placebo 6.9%) sedation 11.3% (placebo 2%) insomnia 9.4% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence 2.5 mg BID somnolence 20.4% (placebo 6.9%) dizziness 7.1% (placebo 1%) headache 7.1% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence insomnia 10.6% weight increased 5.9% headache 2.4% NCT00174265 · Phase 3 · registry result, not featured evidence insomnia 17.6% somnolence 14.8% headache 13.5% NCT00145496 · Phase 3 · registry result, not featured evidence insomnia 20.1% (placebo 24.5%) somnolence 16% (placebo 17.2%) weight increased 14.4% (placebo 10.9%) NCT00150176 · Phase 3 · registry result, not featured evidence headache 5.2% influenza 5.2% schizophrenia 5.2% NCT00265343 · Phase 3 · registry result, not featured evidence insomnia 18.5% headache 10.9% parkinsonism 10.9% NCT00156065 · Phase 3 · registry result, not featured evidence 5 mg dystonia 66.7% dizziness 33.3% nausea 33.3% NCT01206517 · Phase 1 · registry result, not featured evidence 10 mg hypoaesthesia oral 50% dizziness 38.9% dysgeusia 38.9% NCT01206517 · Phase 1 · registry result, not featured evidence 2.5 mg sedation 33.3% dysgeusia 16.7% hypoaesthesia oral 16.7% NCT01206517 · Phase 1 · registry result, not featured evidence | show 13 more resultsbmi increase normal/overweight to obese 31.3% ldl or triglyceride increase 25% prolactin related symptom 12.5% NCT00333177 · Phase 4 · registry result, not featured evidence bmi increase normal/overweight to obese 25% prolactin related symptom 16.7% ldl or triglyceride increase 8.3% NCT00333177 · Phase 4 · registry result, not featured evidence ldl or triglyceride increase 41.7% prolactin related symptom 16.7% bmi increase normal/overweight to obese 0% NCT00333177 · Phase 4 · registry result, not featured evidence bmi increase normal/overweight to obese 12.5% ldl or triglyceride increase 6.3% prolactin related symptom 6.3% NCT00333177 · Phase 4 · registry result, not featured evidence bmi increase from normal or overweight to obese 17.5% prolactin related 7.5% lipid increase 5% NCT00330551 · Phase 4 · registry result, not featured evidence non-serious adverse events 16.7% NCT00539071 · Phase 4 · registry result, not featured evidence akathisisa 10% anxiety 10% muscle rigidity 10% NCT00992407 · Phase 4 · registry result, not featured evidence insomnia 10.2% pain 10.2% vomiting 10.2% NCT00130923 · Phase 4 · registry result, not featured evidence insomnia 8.2% akathisia 7.3% weight increased 7.3% NCT00216671 · Phase 4 · registry result, not featured evidence headache 34.1% insomnia 29.5% fatigue 25% NCT00246259 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 20.5% akathisia 12.8% vision blurred 10.3% NCT00269919 · Phase 4 · registry result, not featured evidence libido decreased 22.6% weight increased 13.2% blood prolactin increased 11.3% NCT01726335 · Phase 4 · registry result, not featured evidence hyperprolactinaemia 13.1% anxiety 11.9% insomnia 10.9% NCT00216476 · Phase 3 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 4.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Asenapine
show 1 more result
show 1 more result
show 17 more results
show 2 more results
show 19 more results
show 15 more results
show 15 more results
show 17 more results
show 17 more results
show 17 more results
show 17 more results
show 17 more results
+ 31 further endpoints in the CSV export.
Risperidone (Risperdal Consta)
show 3 more results
show 7 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
+ 30 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Risperidone (Risperdal Consta)'s landscape